← Back to Clinical Trials
Recruiting NCT07196488

NCT07196488 Dyadic Co-learning Intervention for Patients With Prostate Cancer and Their Spouses

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07196488
Status Recruiting
Phase
Sponsor National Taipei University of Nursing and Health Sciences
Condition Prostate Cancer (Adenocarcinoma)
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-10-13
Primary Completion 2026-07-31

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Dyadic Co-learning Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-10-13 with a primary completion date of 2026-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to help patients with prostate cancer and their spouses cope better with the challenges of cancer by learning and supporting each other together. The investigators will test an 8-week "Dyadic Co-learning Intervention," which includes weekly learning topics, a mobile app, and professional support. The goal is to improve their physical symptoms, emotional well-being, and resilience. Participants will be randomly assigned to one of two groups. One group will receive regular care, while the other group will receive regular care plus the new co-learning program. The investigators will ask both patients and their spouses to complete questionnaires at the beginning of the study, and again at 10 and 16 weeks, to understand how the program affects their health and well-being.

Eligibility Criteria

Inclusion Criteria: For Patients: 1. Diagnosed with prostate cancer by a board-certified urologist. 2. Has either decided on a treatment plan or completed treatment within the past two years. 3. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. For Spouses: 1. Must be a cohabiting spouse of the prostate cancer patient and aged 20 years or older. 2. Must have a Barthel Index score of 91 or above, indicating good functional independence. Exclusion Criteria: Either the patient or the spouse will be excluded if: 1. Diagnosed with another type of cancer. 2. Diagnosed with cognitive impairment or a psychiatric disorder, such as dementia, depression, or anxiety.

Contact & Investigator

Central Contact

Ching-Hui Chien, PhD

✉ chinghui@ntunhs.edu.tw

📞 +886-2-28227101

Principal Investigator

Ching-Hui Chien

PRINCIPAL INVESTIGATOR

National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.

Frequently Asked Questions

Who can join the NCT07196488 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 90 Years, studying Prostate Cancer (Adenocarcinoma). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07196488 currently recruiting?

Yes, NCT07196488 is actively recruiting participants. Contact the research team at chinghui@ntunhs.edu.tw for enrollment information.

Where is the NCT07196488 trial being conducted?

This trial is being conducted at Keelung, Taiwan, Taoyuan, Taiwan.

Who is sponsoring the NCT07196488 clinical trial?

NCT07196488 is sponsored by National Taipei University of Nursing and Health Sciences. The principal investigator is Ching-Hui Chien at National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology